Vaccines for Pseudomonas aeruginosa: a long and winding road

References

• Alexander JW, Fisher MW. Vaccination for Pseudomonas aeruginosa. Am J Surgery 1970;120(4):512
   PubMedGoogle Scholar
• Lanyi B. Serological properties of Pseudomonas aeruginosa. II. Type-specific thermolabile (flagellar) antigens. Acta Microbiol Acad Sci Hung 1970;17(1):35-48
   PubMedGoogle Scholar
• Bartell PF, Orr TE, Chudio B. Purification and chemical composition of the protective slime antigen of Pseudomonas aeruginosa. Infect Immun 1970;2:543-8
   PubMedGoogle Scholar
• Döring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008;26(8):1011-24
   PubMed Web of Science ®Google Scholar
• Worgall S. 40 years on: have we finally got a vaccine for Pseudomonas aeruginosa? Future Microbiol 2012;7(12):1333-5
   PubMed Web of Science ®Google Scholar
• Gaynes R, Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005;41(6):848-54
   PubMed Web of Science ®Google Scholar
• Thirumala R, Ramaswamy M, Chawla S. Diagnosis and management of infectious complications in critically ill patients with cancer. Crit Care Clin 2010;26(1):59-91
   PubMed Web of Science ®Google Scholar
• Carratala J, Roson B, Fernandez-Sevilla A, et al. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med 1998;158(8):868-72
   PubMedGoogle Scholar
• Church D, Elsayed S, Reid O, et al. Burn wound infections. Clin Microbiol Rev 2006;19(2):403-34
   PubMed Web of Science ®Google Scholar
• Murray CK, Wilkins K, Molter NC, et al. Infections complicating the care of combat casualties during operations Iraqi Freedom and Enduring Freedom. J Trauma 2011;71:1(Suppl):S62-73
   PubMedGoogle Scholar
• Petersen K, Riddle MS, Danko JR, et al. Trauma-related infections in battlefield casualties from Iraq. Ann Surg 2007;245(5):803-11
   PubMedGoogle Scholar
• Folkesson A, Jelsbak L, Yang L, et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol 2012;10(12):841-51
   PubMed Web of Science ®Google Scholar
• Driebe WT Jr. Present status of contact lens-induced corneal infections. Ophthalmol Clin North Am 2003;16(3):485-94. viii
   PubMedGoogle Scholar
• Parkins MD, Gregson DB, Pitout JD, et al. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection 2010;38(1):25-32
   PubMed Web of Science ®Google Scholar
• Dantes R, Mu Y, Belflower R, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013;173(21):1970-8
   PubMed Web of Science ®Google Scholar
• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34(1):1-14
   PubMed Web of Science ®Google Scholar
• McEachern R, Campbell GD. Hospital-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am 1998;12(3):761-79
   PubMed Web of Science ®Google Scholar
• Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33(10):2184-93
   PubMed Web of Science ®Google Scholar
• Rello J, Rue M, Jubert P, et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997;25(11):1862-7
   PubMedGoogle Scholar
• Aronson NE, Sanders JW, Moran KA. In harm's way: infections in deployed American military forces. Clin Infect Dis 2006;43(8):1045-51
   PubMed Web of Science ®Google Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168(8):918-51
   PubMed Web of Science ®Google Scholar
• Sibley CD, Grinwis ME, Field TR, et al. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS One 2011;6(7):e22702
   PubMed Web of Science ®Google Scholar
• Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci USA 2012;109(34):13769-74
   PubMed Web of Science ®Google Scholar
• Madan JC, Koestler DC, Stanton BA, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 2012;3(4):e00251-12
   PubMed Web of Science ®Google Scholar
• Confirmatory Phase II/III study assessing efficacy, immunogenicity and safety of IC43. Available from: http://clinicaltrials.gov/show/NCT01563263
   Google Scholar
• Westritschnig K, Hochreiter R, Wallner G, et al. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccin Immunother 2013; [Epub ahead of print]
   PubMedGoogle Scholar
• Fisher MW, Devlin HB, Gnabski F. New immunotype schema for Pseudomonas aeruginosa based on protective antigens. J Bacteriol 1969;98:835-6
   PubMedGoogle Scholar
• Pier GB. Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen. Carbohydr Res 2003;338(23):2549-56
   PubMedGoogle Scholar
• Knirel YA. Polysaccharide antigens of Pseudomonas aeruginosa. CRC Crit Rev Microbiol 1990;17:273-304
   Google Scholar
• Alexander JW, Fisher MW, MacMillan BG. Immunological control of Pseudomonas infection in burn patients: a clinical evaluation. Arch Surgery 1971;102(1):31-5
   PubMedGoogle Scholar
• Young LS, Meyer RD, Armstrong D. Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med 1973;79(4):518-27
   PubMed Web of Science ®Google Scholar
• Haghbin M, Armstrong D, Murphy ML. Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia. Cancer 1973;32(4):761-6
   PubMedGoogle Scholar
• Pennington JE, Reynolds HY, Wood RE, et al. Use of a Pseudomonas aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis. Am J Med 1975;58(5):629-36
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr, Furer E, Germanier R. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun 1984;43(3):795-9
   PubMed Web of Science ®Google Scholar
• Pier GB, Thomas D, Small G, et al. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide. Infect Immun 1989;57(1):174-9
   PubMedGoogle Scholar
• Hatano K, Pier GB. Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains. Infect Immun 1998;66(8):3719-26
   PubMed Web of Science ®Google Scholar
• Hatano K, Boisot S, DesJardins D, et al. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa. Infect Immun 1994;62(9):3608-16
   PubMed Web of Science ®Google Scholar
• Donta ST, Peduzzi P, Cross AS, et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J Infect Dis 1996;174(3):537-43
   PubMedGoogle Scholar
• Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012;18(4):509-19
   PubMed Web of Science ®Google Scholar
• Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996;271(5245):64-7
   PubMed Web of Science ®Google Scholar
• Goss CH, Ratjen F. Update in cystic fibrosis. 2012;Am J Respir Crit Care Med 2013;187(9):915-19
   Google Scholar
• Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012;487(7405):109-13
   PubMed Web of Science ®Google Scholar
• Pedersen SS, Hoiby N, Espersen F, Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 1992;47:6-13
   PubMed Web of Science ®Google Scholar
• Parad RB, Gerard CJ, Zurakowski D, et al. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 1999;67(9):4744-50
   PubMed Web of Science ®Google Scholar
• Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183(3):444-52
   PubMed Web of Science ®Google Scholar
• Hancock REW, Mutharia LM, Chan L, et al. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, non-typeable strains deficient in lipopolysaccharide O side-chains. Infect Immun 1983;42:170-7
   PubMed Web of Science ®Google Scholar
• Pier GB, Saunders JM, Ames P, et al. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. New Engl J Med 1987;317(13):793-8
   PubMedGoogle Scholar
• Pier GB, Small GJ, Warren HB. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 1990;249(4968):537-40
   PubMedGoogle Scholar
• Pier GB, DesJardin D, Grout M, et al. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect Immun 1994;62(9):3972-9
   PubMed Web of Science ®Google Scholar
• Pier GB, Takeda S, Grout M, Markham RB. Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa. J Clin Invest 1993;91(3):1079-87
   PubMedGoogle Scholar
• Bragonzi A, Worlitzsch D, Pier GB, et al. Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J Infect Dis 2005;192(3):410-19
   PubMed Web of Science ®Google Scholar
• Pier GB, Boyer D, Preston M, et al. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol 2004;173(9):5671-8
   PubMed Web of Science ®Google Scholar
• Johansen HK, Gotzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2013;6:CD001399
   PubMedGoogle Scholar
• Doering G, Meisner C, Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci USA 2007;104(26):11020-5
   PubMedGoogle Scholar
• Campodonico VL, Llosa NJ, Bentancor LV, et al. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Infect Immun 2011;79(8):3455-64
   PubMedGoogle Scholar
• Lang AB, Rudeberg A, Schoni MH, et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 2004;23(6):504-10
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr, Lang A, Rudeberg A, et al. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst Mitt 1997(98):345-9
   PubMedGoogle Scholar
• Priebe GP, Brinig MM, Hatano K, et al. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect Immun 2002;70(3):1507-17
   PubMed Web of Science ®Google Scholar
• Priebe GP, Meluleni GJ, Coleman FT, et al. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun 2003;71(3):1453-61
   PubMed Web of Science ®Google Scholar
• Priebe GP, Walsh RL, Cederroth TA, et al. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol 2008;181(7):4965-75
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6(11):1123-32
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13(2):139-45
   PubMed Web of Science ®Google Scholar
• Kolls JK, Kanaly ST, Ramsay AJ. Interleukin-17: an emerging role in lung inflammation. Am J Respir Cell Mol Biol 2003;28(1):9-11
   PubMed Web of Science ®Google Scholar
• Ye P, Garvey PB, Zhang P, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 2001;25(3):335-40
   PubMed Web of Science ®Google Scholar
• Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin-17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194(4):519-27
   PubMed Web of Science ®Google Scholar
• Chen K, McAleer JP, Lin Y, et al. Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity 2011;35(6):997-1009
   PubMed Web of Science ®Google Scholar
• Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177(1):566-73
   PubMed Web of Science ®Google Scholar
• Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of TH17 cells. Nature 2008;453:1051-7
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006;441(7090):231-4
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24(2):179-89
   PubMed Web of Science ®Google Scholar
• Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52
   PubMed Web of Science ®Google Scholar
• Codarri L, Gyulveszi G, Tosevski V, et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011;12(6):560-7
   PubMed Web of Science ®Google Scholar
• El-Behi M, Ciric B, Dai H, et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 2011;12(6):568-75
   PubMed Web of Science ®Google Scholar
• Happel KI, Zheng M, Young E, et al. Cutting Edge: roles of Toll-Like Receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 2003;170(9):4432-6
   PubMed Web of Science ®Google Scholar
• McAllister F, Henry A, Kreindler JL, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005;175(1):404-12
   PubMed Web of Science ®Google Scholar
• Tiringer K, Treis A, Fucik P, et al. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013;187(6):621-9
   PubMed Web of Science ®Google Scholar
• Tan HL, Regamey N, Brown S, et al. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011;184(2):252-8
   PubMed Web of Science ®Google Scholar
• Sorensen RU, Stern RC, Polmar SH. Cellular immunity to bacteria: impairment of in vitro lymphocyte responses to Pseudomonas aeruginosa in cystic fibrosis patients. Infect Immun 1977;18(3):735-40
   PubMedGoogle Scholar
• Sorensen RU, Stern RC, Polmar SH. Lymphocyte responsiveness to Pseudomonas aeruginosa in cystic fibrosis: relationship to status of pulmonary disease in sibling pairs. J Pediatr 1978;93(2):201-5
   PubMedGoogle Scholar
• Krauss RD, Bubien JK, Drumm ML, et al. Transfection of wild-type CFTR into cystic fibrosis lymphocytes restores chloride conductance at G1 of the cell cycle. EMBO J 1992;11(3):875-83
   PubMedGoogle Scholar
• Kamei A, Wu W, Traficante DC, et al. Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia. J Infect Dis 2013;207(1):39-49
   PubMed Web of Science ®Google Scholar
• Koh AY, Priebe GP, Ray C, et al. Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect Immun 2009;77(12):5300-10
   PubMedGoogle Scholar
• Kamei A, Coutinho-Sledge YS, Goldberg JB, et al. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect Immun 2011;79(3):1289-99
   PubMed Web of Science ®Google Scholar
• Wu W, Huang J, Traficante DC, et al. Construction and evaluation of live-attenuated vaccines for Pseudomonas aeruginosa serogroup O11 strains (abstract 2339). American Society for Microbiology Meeting; San Francisco, CA, USA; 2012
   Google Scholar
• Zaidi TS, Priebe GP, Pier GB. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect Immun 2006;74(2):975-83
   PubMed Web of Science ®Google Scholar
• Zaidi TS, Lyczak J, Preston M, Pier GB. Cystic fibrosis transmembrane conductance regulator-mediated corneal epithelial cell ingestion of Pseudomonas aeruginosa is a key component in the pathogenesis of experimental murine keratitis. Infect Immun 1999;67(3):1481-92
   PubMed Web of Science ®Google Scholar
• Zaidi TS, Zaidi T, Pier GB, Priebe GP. Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology. Infect Immun 2012;80(10):3706-12
   PubMedGoogle Scholar
• Faure K, Shimabukuro D, Ajayi T, et al. O-Antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa. J Clin Microbiol 2003;41(5):2158-60
   PubMed Web of Science ®Google Scholar
• DiGiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica Serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun 2004;72(12):7012-21
   PubMedGoogle Scholar
• DiGiandomenico A, Rao J, Harcher K, et al. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc Natl Acad Sci USA 2007;104(11):4624-9
   PubMedGoogle Scholar
• Scarff JM, Goldberg JB. Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice. Clin Vaccine Immunol 2007;15(2):367-75
   PubMedGoogle Scholar
• Wu W, Huang J, Duan B, et al. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2012;186(5):420-7
   PubMedGoogle Scholar
• Montor WR, Huang J, Hu Y, et al. Genome-wide study of Pseudomonas aeruginosa outer membrane protein immunogenicity using self-assembling protein microarrays. Infect Immun 2009;77(11):4877-86
   PubMed Web of Science ®Google Scholar
• Feltman H, Schulert G, Khan S, et al. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001;147(Pt 10):2659-69
   PubMed Web of Science ®Google Scholar
• Koh AY, Mikkelsen PJ, Smith RS, et al. Utility of in vivo transcription profiling for identifying Pseudomonas aeruginosa genes needed for gastrointestinal colonization and dissemination. PLoS One 2010;5(12):e15131
   PubMed Web of Science ®Google Scholar
• Smith EE, Sims EH, Spencer DH, et al. Evidence for diversifying selection at the pyoverdine locus of Pseudomonas aeruginosa. J Bacteriol 2005;187(6):2138-47
   PubMedGoogle Scholar
• Pirnay JP, Bilocq F, Pot B, et al. Pseudomonas aeruginosa population structure revisited. PLoS ONE 2009;4(11):e7740
   PubMed Web of Science ®Google Scholar
• Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006;103(22):8487-92
   PubMed Web of Science ®Google Scholar
• Kankkunen P, Teirila L, Rintahaka J, et al. (1,3)-beta-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. J Immunol 2010;184(11):6335-42
   PubMed Web of Science ®Google Scholar
• Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA. Intranasal immunization promotes Th17 immune responses. J Immunol 2009;183(11):6933-8
   PubMed Web of Science ®Google Scholar
• Leibundgut-Landmann S, Gross O, Robinson MJ, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007;8(6):630-8
   PubMed Web of Science ®Google Scholar
• Brennan FR, Jones TD, Gilleland LB, et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. Microbiology 1999;145(Pt 1):211-20
   PubMedGoogle Scholar
• Mansouri E, Gabelsberger J, Knapp B, et al. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect Immun 1999;67(3):1461-70
   PubMed Web of Science ®Google Scholar
• Matthews-Greer JM, Robertson DEL.B.G, Gilleland HE Jr. Pseudomonas aeruginosa outer membrane protein F produced in Escherichia coli retains vaccine efficacy. Curr Microbiol 1990;20:171-5
   Web of Science ®Google Scholar
• Krause A, Whu WZ, Qiu J, et al. RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF. Clin Exp Immunol 2013;173(2):230-41
   PubMed Web of Science ®Google Scholar
• Sharma A, Krause A, Xu Y, et al. Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosa. PLoS One 2013;8(2):e56996
   PubMed Web of Science ®Google Scholar
• Toth A, Schodel F, Duchene M, et al. Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin. Vaccine 1994;12(13):1215-21
   PubMedGoogle Scholar
• Duchene M, Barron C, Schweizer A, et al. Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli. J Bacteriol 1989;171(8):4130-7
   PubMed Web of Science ®Google Scholar
• Finke M, Duchene M, Eckhardt A, et al. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infect Immun 1990;58:2241-4
   PubMed Web of Science ®Google Scholar
• Mutharia LM, Nicas TI, Hancock RE. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J Infect Dis 1982;146(6):770-9
   PubMedGoogle Scholar
• Ding B, von Specht BU, Li Y. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa. Vaccine 2010;28(25):4119-22
   PubMedGoogle Scholar
• Gilleland HE Jr, Parker MG, Matthews JM, Berg RD. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect Immun 1984;44(1):49-54
   PubMedGoogle Scholar
• Fox CW, Campbell GD Jr, Anderson WM, et al. Preservation of pulmonary function by an outer membrane protein F vaccine. A study in rats with chronic pulmonary infection caused by Pseudomonas aeruginosa. Chest 1994;105(5):1545-50
   PubMedGoogle Scholar
• Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Hum Vaccin 2011;7(10):999-1011
   PubMed Web of Science ®Google Scholar
• Hughes EE, Gilleland HE Jr. Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model. Vaccine 1995;13(18):1750-3
   PubMedGoogle Scholar
• Worgall S, Kikuchi T, Singh R, et al. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infect Immun 2001;69(7):4521-7
   PubMedGoogle Scholar
• von Specht BU, Knapp B, Muth G, et al. Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect Immun 1995;63(5):1855-62
   PubMedGoogle Scholar
• Knapp B, Hundt E, Lenz U, et al. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa. Vaccine 1999;17(13-14):1663-6
   PubMedGoogle Scholar
• Weimer ET, Lu H, Kock ND, et al. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect Immun 2009;77(6):2356-66
   PubMedGoogle Scholar
• Weimer ET, Ervin SE, Wozniak DJ, Mizel SB. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 2009;27(48):6762-9
   PubMedGoogle Scholar
• von Specht BU, Lucking HC, Blum B, et al. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers. Vaccine 1996;14(12):1111-17
   PubMedGoogle Scholar
• Wu L, Estrada O, Zaborina O, et al. Recognition of host immune activation by Pseudomonas aeruginosa. Science 2005;309(5735):774-7
   PubMed Web of Science ®Google Scholar
• Worgall S, Krause A, Rivara M, et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 2005;115:1281-9
   PubMed Web of Science ®Google Scholar
• Sato H, Frank DW. Multi-functional characteristics of the Pseudomonas aeruginosa type III needle-tip protein, PcrV; comparison to orthologs in other Gram-negative bacteria. Front Microbiol 2011;2:142
   PubMedGoogle Scholar
• Sawa T, Yahr TL, Ohara M, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999;5(4):392-8
   PubMed Web of Science ®Google Scholar
• Shime N, Sawa T, Fujimoto J, et al. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol 2001;167(10):5880-6
   PubMedGoogle Scholar
• Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002;186(1):64-73
   PubMedGoogle Scholar
• Baer M, Sawa T, Flynn P, et al. An engineered human antibody Fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009;77(3):1083-90
   PubMedGoogle Scholar
• Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002;54(4):531-45
   PubMed Web of Science ®Google Scholar
• Francois B, Luyt CE, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012;40(8):2320-6
   PubMed Web of Science ®Google Scholar
• Milla CE, Chmiel JF, Accurso FJ, et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa. Available from: http://clinicaltrials.gov/show/NCT00638365
   Google Scholar
• Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment. Available from: http://clinicaltrials.gov/show/NCT01695343
   Google Scholar
• Carlander D, Kollberg H, Wejaker PE, Larsson A. Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections. Immunol Res 2000;21(1):1-6
   PubMed Web of Science ®Google Scholar
• Kollberg H, Carlander D, Olesen H, et al. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 2003;35(6):433-40
   PubMed Web of Science ®Google Scholar
• Anti-pseudomonas IgY to prevent infections in cystic fibrosis (PseudIgY). Available from: http://clinicaltrials.gov/show/NCT00633191
   Google Scholar
• Nilsson E, Larsson A, Olesen HV, et al. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol 2008;43(9):892-9
   PubMed Web of Science ®Google Scholar
• Efficacy Study of IgY (antibody against pseudomonas) in cystic fibrosis patients (PsAer-IgY). Available from: http://clinicaltrials.gov/show/NCT01455675
   Google Scholar
• Cryz SJ Jr, Furer E, Sadoff JC, Germanier R. A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Antibiot Chemother 1987;39:249-55
   PubMedGoogle Scholar
• Cryz SJ Jr, Sadoff JC, Furer E. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Microb Pathog 1989;6(1):75-80
   PubMed Web of Science ®Google Scholar
• Horn MP, Zuercher AW, Imboden MA, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother 2010;54(6):2338-44
   PubMed Web of Science ®Google Scholar
• Secher T, Fauconnier L, Szade A, et al. Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection. J Antimicrob Chemother 2011;66(5):1100-9
   PubMed Web of Science ®Google Scholar
• Lazar H, Horn MP, Zuercher AW, et al. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob Agents Chemother 2009;53(8):3442-6
   PubMed Web of Science ®Google Scholar
• Lu Q, Rouby JJ, Laterre PF, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 2011;66(5):1110-16
   PubMed Web of Science ®Google Scholar
• Safety and pharmacokinetics of KBPA-101 in hospital acquired pneumonia caused by O11 Pseudomonas aeruginosa. Available from: http://clinicaltrials.gov/show/NCT00851435
   Google Scholar
• Hemachandra S, Kamboj K, Copfer J, et al. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal Pseudomonas sepsis. Infect Immun 2001;69(4):2223-9
   PubMed Web of Science ®Google Scholar
• Lai Z, Kimmel R, Petersen S, et al. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal Pseudomonas sepsis caused by multiple serotypes. Vaccine 2005;23(25):3264-71
   PubMedGoogle Scholar
• Zaidi T, Bajmoczi M, Golan DE, Pier GB. Disruption of CFTR-dependent lipid rafts reduces bacterial levels and corneal disease in a murine model of Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2008;49(3):1000-9
   PubMed Web of Science ®Google Scholar
• Zaidi TS, Zaidi T, Pier GB. Role of neutrophils, MyD88-mediated neutrophil recruitment, and complement in antibody-mediated defense against Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2010;51(4):2085-93
   PubMedGoogle Scholar
• Byrd MS, Sadovskaya I, Vinogradov E, et al. Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production. Mol Microbiol 2009;73(4):622-38
   PubMed Web of Science ®Google Scholar
• DiGiandomenico A, Warrener P, Hamilton M, et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 2012;209(7):1273-87
   PubMed Web of Science ®Google Scholar
• Li H, Mo KF, Wang Q, et al. Epitope mapping of monoclonal antibodies using synthetic oligosaccharides uncovers novel aspects of immune recognition of the Psl exopolysaccharide of Pseudomonas aeruginosa. Chemistry (Easton) 2013;19(51):17425-31
   Google Scholar